<DOC>
	<DOCNO>NCT01782833</DOCNO>
	<brief_summary>This Post Marketing Observational Study cilostazol ( Pletaal® SR capsule ) . As study observational nature collect safety data administrate Pletaal SR capsule , baseline 16 week .</brief_summary>
	<brief_title>Pletaal SR Post Marketing Observational Study</brief_title>
	<detailed_description>This study conduct prospective , single-arm , multi-center format . As study observational nature , patient 's follow-up prescriptive nature must leave judgment physician ( investigator ) , within period observation set forth protocol .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Patients must meet follow inclusion criterion eligible enrollment study : 1 . Patients prescribed Pletaal® SR capsule treatment per investigator 's medical judgment adult age 19 . 2 . Patients give write authorization use personal health data Physician ( Investigator ) refer product market authorization ( package insert ) inclusion criterion . Patients present follow include study 1 . Patients hemorrhage 2 . Patients congestive heart failure 3 . Patients know hypersensitivity Cilostazole ingredient Pletaal® 4 . Women pregnant may possibly become pregnant 5 . Patients eligible participate study investigator 's medical judgment Physician ( Investigator ) refer product market authorization ( package insert ) exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>